ArticleOncogenesis2026

Combined therapy with ALK inhibitors and a novel EGFR-targeting antibody‒drug conjugate as a strategy for ALK-rearranged non-small cell lung cancers.

Lanwen Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.